Cytogenetic alterations in prostate cancer [Zytogenetische veranderungen des prostatakarzinoms]

被引:0
|
作者
Sauter G. [1 ,3 ]
Bubendorf L. [1 ]
Moch H. [1 ]
Gasser Th.C. [2 ]
Mihatsch M.J. [1 ]
机构
[1] Institut fur Pathologie, Universitatskliniken, Kantonsspital Basel, CH-4003 Basel
来源
Der Pathologe | 1998年 / 19卷 / 1期
关键词
Cytogenetics; Gene amplification; Polysomy; Prostate cancer;
D O I
10.1007/s002920050256
中图分类号
学科分类号
摘要
Development and progression of tumors is driven by a malfunction of specific genes. Although prostate cancer is one of the most frequent tumors, little is known about the genes involved. Cytogenetic and molecular examinations have shown that chromosomal deletions most frequently involve 7q, 8p, 10q, 13q, 16q, 17p and the Y chromosome. These loci may carry tumor suppressor genes with relevance for prostate cancer. DNA sequence copy number gains were most frequently observed at chromosomes 7, 8q, and 11q. These regions may carry currently unknown oncogenes. There is increasing evidence for a clinical relevance of genetic alterations. Polysomies of several chromosomes were shown to be associated with poor prognosis of prostate cancer patients. Androgen receptor amplification can be found in hormone- refractory carcinomas which may respond to total androgen blockage. For the future it is hoped that the identification of the genes involved in prostate cancer and the determination of their function could allow for significant improvements of treatment strategies for prostate cancer patients.
引用
收藏
页码:63 / 68
页数:5
相关论文
共 50 条
  • [41] Seed Displacements after Permanent Brachytherapy for Prostate Cancer in Dependence on the Prostate LevelSeedverschiebungen nach permanenter Brachytherapie des Prostatakarzinoms in Abhängigkeit vom Prostatalevel
    Michael Pinkawa
    Bernd Gagel
    Branka Asadpour
    Marc D. Piroth
    Jens Klotz
    Holger Borchers
    Gerhard Jakse
    Michael J. Eble
    Strahlentherapie und Onkologie, 2008, 184 : 520 - 525
  • [42] MR techniques for noninvasive diagnosis of prostate cancer [MR-techniken zur nicht-invasiven diagnostik des prostatakarzinoms]
    Morakkabati-Spitz N.
    Bastian P.J.
    Meißner A.
    Träber F.
    Gieseke J.
    Schild H.H.
    Müller S.C.
    Der Urologe, 2006, 45 (6): : 702 - 706
  • [43] Antihormonelle Therapie des Prostatakarzinoms der 3. GenerationThird generation anti-androgen therapy of advanced prostate cancer
    C.-H. Ohlmann
    J. Kamradt
    M. Stöckle
    Der Urologe, 2012, 51 : 522 - 526
  • [44] Pharmacological potential of phytoestrogens in the treatment of prostate cancer [Das pharmakologische potential von phytoöstrogenen in der therapie des prostatakarzinoms]
    Thelen P.
    Seseke F.
    Ringert R.-H.
    Wuttke W.
    Seidlová-Wuttke D.
    Der Urologe, 2006, 45 (2): : 195 - 201
  • [45] Therapie des lokalisierten Prostatakarzinoms mit hochintensivem fokussierten UltraschallTreatment of localized prostate cancer with high-intensity focused ultrasound
    D. Baumunk
    M. Schostak
    Der Urologe, 2015, 54 (2): : 183 - 190
  • [46] Controversies in the therapy of high-risk prostate cancer: Radiotherapy [Kontroversen der Therapie des Hochrisiko-Prostatakarzinoms: Strahlentherapie]
    Böhmer D.
    Der Onkologe, 2015, 21 (9): : 805 - 814
  • [47] Irreversible electroporation: Current value for focal treatment of prostate cancer [Irreversible Elektroporation: Aktueller Stellenwert in der fokalen Therapie des Prostatakarzinoms]
    Wendler J.J.
    Ganzer R.
    Hadaschik B.
    Blana A.
    Henkel T.
    Köhrmann K.U.
    Machtens S.
    Roosen A.
    Salomon G.
    Sentker L.
    Witzsch U.
    Schlemmer H.P.
    Baumunk D.
    Köllermann J.
    Schostak M.
    Liehr U.B.
    Der Urologe, 2015, 54 (6): : 854 - 862
  • [48] Cytogenetic alterations in nonmelanoma skin cancer: A review
    Ashton, KJ
    Carless, MA
    Griffiths, LR
    GENES CHROMOSOMES & CANCER, 2005, 43 (03): : 239 - 248
  • [49] Erratum to: Hypofractionated radiotherapy for localized prostate cancerErratum zu: Hypofraktionierte Radiotherapie des lokalisierten Prostatakarzinoms
    Stefan Höcht
    Daniel M. Aebersold
    Clemens Albrecht
    Dirk Böhmer
    Michael Flentje
    Ute Ganswindt
    Tobias Hölscher
    Thomas Martin
    Felix Sedlmayer
    Frederik Wenz
    Daniel Zips
    Thomas Wiegel
    Strahlentherapie und Onkologie, 2016, 192 (11) : 830 - 830
  • [50] Molecular cytogenetic characterization of cancer cell alterations
    Popescu, NC
    Zimonjic, DB
    CANCER GENETICS AND CYTOGENETICS, 1997, 93 (01) : 10 - 21